We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
+27.6%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
+$179M
Cap. Flow
+$103M
Cap. Flow %
20.69%
Top 10 Hldgs %
99.49%
Holding
11
New
2
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$88.3M
2
ORKA
Oruka Therapeutics
ORKA
+$13.1M
3
ENGN icon
enGene Therapeutics
ENGN
+$1.84M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$196M 39.29%
2,346,630
– –
ZBIO
2
Zenas BioPharma
ZBIO
$2.05B
$83.1M 16.66%
+4,911,539
New +$88.3M
SPRY icon
3
ARS Pharmaceuticals
SPRY
$591M
$58.2M 11.67%
4,012,903
– –
CRSP icon
4
CRISPR Therapeutics
CRSP
$5.23B
$49.3M 9.88%
1,048,951
– –
DSGN icon
5
Design Therapeutics
DSGN
$915M
$35.1M 7.04%
6,526,476
– –
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.41B
$24.4M 4.9%
2,016,822
– –
ALMS
7
Alumis Inc
ALMS
$3.23B
$20.9M 4.2%
1,959,896
– –
NKTX icon
8
Nkarta
NKTX
$167M
$15.1M 3.02%
3,333,333
– –
ORKA
9
Oruka Therapeutics
ORKA
$6.31B
$9.2M 1.84%
+375,330
New +$13.1M
ENGN icon
10
enGene Therapeutics
ENGN
$122M
$4.94M 0.99%
747,750
+247,750
+50% +$1.84M
KALA icon
11
KALA BIO
KALA
$16.3M
$2.53M 0.51%
8,873
– –

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, SR One Capital Management held 11 positions worth $499M, up 56% from $319M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

SR One Capital Management deployed $103M of net new capital in Q3 2024, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Zenas BioPharma: 4,911,539 shares worth $83.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q3 2024 buy was Zenas BioPharma: 4,911,539 shares worth $83.1M.
  • SR One Capital Management added most to enGene Therapeutics in Q3 2024, an estimated $1.84M increase.
  • SR One Capital Management's ten largest holdings make up 99% of its $499M portfolio in Q3 2024.
  • SR One Capital Management opened 2 new positions and closed 0 in Q3 2024.
  • SR One Capital Management's portfolio value rose 56% quarter-over-quarter to $499M.

Based on SR One Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.